The PADCEV was evaluated in P-II EV-201 Trial to evaluate 125 patients locally advanced or metastatic urothelial cancer who received who received prior treatment with a PD-1 or PD-L1 inhibitor and a Pt-based CT The study resulted in ORR 44%, CR 12% leading no cancer detection at time of assessment, PR 32% meaning a decrease […]Read More
Shots: The P-II EV-201 study involves assessing of Enfortumab Vedotin in patients with locally advanced or metastatic urothelial cancer who have been previously treated with a PD-1/L1 inhibitor including those who have also been treated with Pt-CT P-II EV-201 results: ORR 44%; DOR 7.6 mos.; mOS 11.7 mos.; mPFS 5.8 mos.; CR 12%; presented at […]Read More
Shots: Basilea to conduct the P-I/II biomarker-driven clinical trial with its expected initiation in H1’2019 and Roche to provide atezolizumab for the trial The focus of the agreement is for the onset of the trial assessing Basilea’s derazantinib in combination with Roche’s Tecentriq (atezolizumab) in patients with advanced (UC) and FGFR genomic defects Derazantinib (BAL087, formerly ARQ 087) is […]Read More
Copyright ©2020 PharmaShots | Powered by Octavus Consulting
